EN DE
Watch Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (688221) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A stock ¥9.72, price ¥13.70, that is 29.1% below the price, quality 37 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CN · ISIN CNE100005XF5

FB Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A logo Thin data Nov 10, 2026

Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A

688221 · SHG
Expensive, weak quality

Our calculation puts a fair price 29% below what the stock costs today.

Low debt
Expensive Growth (revenue 5y +21.5 %/yr in CNY)
Revenue last quarter 47% below a year ago.
Fair value ¥9.72 · Overvalued
Quality 37/100
Loss-making · -5.8% net margin (TTM)
Negative free cash flow
Trails peers (0/10)
Narrow moat 6/100
Thin data
Estimate
Watch Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥28.15 ¥4.55 Fair Value ¥9.72 Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range ¥4.55 – ¥28.15 · fair‑value band ¥7.29 – ¥12.14 · the ¥13.70 price screens above the ¥9.72 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A in your weekly email

Every Wednesday you see whether Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patients' health in China.

Show moreShow less

It offers Aikening, a long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS. The company's products under development include small RNA drugs, such as FB7011/FB7013/FB7014 to treat IgA nephropathy, FB7022/FB7021 for dyslipidemia, and FB7012/FB7041/FB7031/FB7032 for various other diseases, including hyperuricemia and gout, tumors, and metabolic-associated fatty liver diseases; FB4001, to treat patients with osteoporosis or high risk of fracture; and FB3002, for the treatment of pain in muscles, bones, and joints.

Frontier Biotechnologies Inc. was founded in 2002 and is headquartered in Nanjing, China.

Stock analysis

Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (688221) currently trades at ¥13.70, while our estimate is ¥9.72, 29% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: ¥7.29 (bear) to ¥12.14 (bull), the price of ¥13.70 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A reported revenue of 123M CNY in FY2025 versus 40.5M CNY in FY2021, a compound +32.1%/yr. Reported net income was −268M CNY in FY2025.

Key figures

Market cap 5.1B CNY (≈ $770M) Small · P/S ratio 13.3 · EPS (TTM) ¥−0.0600 · Dividend yield 0.2% · Net margin −5.8% · Return on equity −2.1% · Return on assets (EBIT) −14.3% (5-year average) · Operating margin −579%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (medium confidence).

What moves the price

The share trades about 51% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −29%, 688221 screens richer than that median.

Fair Value

Bear ¥7.29 Fair Value ¥9.72 Bull ¥12.14
Price ¥13.70 · Downside -29.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 37/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 20
Are margins and returns getting better?
Cashflow 8
Do the profits arrive as real cash?
Financial strength 67
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 36
How calm the share price moves, does not count
Price momentum 19
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 19
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 32/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−4.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.5%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+34.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−507.7% (2020) → −195.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

688221 screens overvalued: fair value 29% below the price. Compare with Merck KGaA →

Compare Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 606 stocks

Beats the industry median on 0/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 37 · Bottom 25%
Fair Value upside −29.1% · Below median
Profitability
Return on assets −17.0% · Bottom 25%
Net margin (12 months) −5.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −46.7% · Bottom 25%
Dividend yield (12 months) 0.2% · Bottom 25%
Balance sheet
Debt / equity 0.09× · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 5.85× · Priciest 25%
P/S (12 months) 13.57× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 18
FUTURE (revenue growth)0 · sector 25
PAST (return on equity)0 · sector 25
HEALTH (low debt)95 · sector 96
DIVIDEND (yield)3 · sector 31

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $82.46 $113.53 +38% vs 688221
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.55 ¥55.21 +14% vs 688221
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,905 ₹1,983 +4% vs 688221
Haleon plc HLN $9.06 $8.62 −5% vs 688221
Merck KGaA MRK €149.35 €109.18 −27% vs 688221
Galderma Group GALD CHF 188.55 CHF 109.80 −42% vs 688221
Takeda Pharmaceutical Company TAK $20.93 $11.34 −46% vs 688221
Teva Pharmaceutical Industries Limited TEVA $42.40 $20.74 −51% vs 688221
Sandoz Group SDZ CHF 83.38 CHF 39.70 −52% vs 688221
Divi's Laboratories Limited DIVISLAB ₹11,566 ₹1,567 −86% vs 688221

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A Fair Value". https://www.fairvalue-calculator.com/stock/688221

Frequently asked questions

Is Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (688221) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is ¥9.72 versus a price of ¥13.70, about 29% lower (overvalued).
What is the fair value of 688221?
Our estimate for Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A is ¥9.72 (as of Nov 10, 2026), built from audited fundamentals. The current price: ¥13.70.
What is the quality score of 688221?
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (688221)?
Our calculated price target is the estimate of ¥9.72 (as of Nov 10, 2026). Cautious scenario ¥7.29, optimistic scenario ¥12.14. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A stock forecast for 2026?
Our estimate puts fair value at ¥9.72, about 29% lower versus a price of ¥13.70 (overvalued). Cautious scenario ¥7.29, optimistic scenario ¥12.14. The calculation is refreshed regularly with new filings.
Does Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A pay a dividend?
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A currently shows a dividend yield of 0.16% relative to its recent price (as of Nov 10, 2026).
How much is the dividend of Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (688221)?
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A has a dividend yield of 0.2%.
What is the intrinsic value of Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (688221)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A it is ¥9.72 per share (as of Nov 10, 2026), against a price of ¥13.70.
Is Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 688221 trades above its calculated fair value: price ¥13.70, fair value ¥9.72, a gap of about −29% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688221?
No. The price is what the market pays today (¥13.70); the fair value is what the company's own numbers justify (¥9.72). For Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A the two are ¥3.98 per share apart. That gap is exactly why we show both numbers side by side.
How much is Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A worth?
The market values Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A at about 5.1B CNY (market capitalisation, as of Nov 10, 2026). Per share that is ¥13.70; our models calculate a fair value of ¥9.72 per share.
What do the bullish and bearish scenarios say about 688221?
Our models span a range for Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A: cautious scenario ¥7.29, base ¥9.72, optimistic ¥12.14 per share (as of Nov 10, 2026, price ¥13.70). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (688221)?
Balance-sheet figures for Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (as of Nov 10, 2026): return on equity −2.1%, debt of 0.09 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is 688221 from its 52-week high?
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A trades at ¥13.70, about 51% below its 52-week high of ¥28.15 and 12% above the low of ¥12.28 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of ¥9.72 is for.
Which stocks are comparable to Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A stock attractive at the current price?
The data as of Nov 10, 2026: price ¥13.70, calculated fair value ¥9.72 (−29%), Quality Score 37/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (688221)?
The closing price on Nov 10, 2026 was ¥13.70. Our estimate is ¥9.72, about 29% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A right now?
The price sits above even our optimistic bull case (¥12.14). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A

How large is the market capitalisation of Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (688221)?
The market capitalisation of Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A is 5.1B CNY (≈ $770M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (688221)?
The price-to-sales ratio of Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A is 13.3 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (688221)?
Earnings per share at Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A are ¥−0.0600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (688221)?
The dividend yield of Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A is 0.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (688221)?
The net margin of Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A is −5.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (688221)?
The return on equity (ROE) of Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A is −2.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (688221)?
On an EBIT basis the return on assets of Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A is −14.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (688221)?
The operating margin of Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A is −579% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (688221)?
Revenue at Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A is growing −46.7% versus a year earlier (3y avg +13.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (688221) generate?
The free cash flow of Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A is −256M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (688221) carry?
The net debt of Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A is 162M CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A in the live analysis

One click puts Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.